RU2166330C2 - Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона - Google Patents

Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона Download PDF

Info

Publication number
RU2166330C2
RU2166330C2 RU98100250/14A RU98100250A RU2166330C2 RU 2166330 C2 RU2166330 C2 RU 2166330C2 RU 98100250/14 A RU98100250/14 A RU 98100250/14A RU 98100250 A RU98100250 A RU 98100250A RU 2166330 C2 RU2166330 C2 RU 2166330C2
Authority
RU
Russia
Prior art keywords
epoxy
antagonist
angiotensin
hydroxy
receptor antagonist
Prior art date
Application number
RU98100250/14A
Other languages
English (en)
Russian (ru)
Other versions
RU98100250A (ru
Inventor
С. АЛЕКСАНДЕР Джон
Р. ШУХ Джозеф
Дж. Горжински Ричард
Original Assignee
Джи. Ди. Сирл Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи. Ди. Сирл Энд Ко. filed Critical Джи. Ди. Сирл Энд Ко.
Publication of RU98100250A publication Critical patent/RU98100250A/ru
Application granted granted Critical
Publication of RU2166330C2 publication Critical patent/RU2166330C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
RU98100250/14A 1995-06-07 1996-06-05 Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона RU2166330C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48645695A 1995-06-07 1995-06-07
US08/486,456 1995-06-07

Publications (2)

Publication Number Publication Date
RU98100250A RU98100250A (ru) 1999-09-27
RU2166330C2 true RU2166330C2 (ru) 2001-05-10

Family

ID=23931955

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98100250/14A RU2166330C2 (ru) 1995-06-07 1996-06-05 Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона

Country Status (21)

Country Link
US (1) US6653306B1 (cg-RX-API-DMAC7.html)
EP (1) EP0831910B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11507627A (cg-RX-API-DMAC7.html)
KR (1) KR100618466B1 (cg-RX-API-DMAC7.html)
CN (2) CN1142793C (cg-RX-API-DMAC7.html)
AT (1) ATE209047T1 (cg-RX-API-DMAC7.html)
AU (1) AU725689B2 (cg-RX-API-DMAC7.html)
BR (1) BR9609066A (cg-RX-API-DMAC7.html)
CA (1) CA2224079A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ297975B6 (cg-RX-API-DMAC7.html)
DE (1) DE69617235T2 (cg-RX-API-DMAC7.html)
DK (1) DK0831910T3 (cg-RX-API-DMAC7.html)
ES (1) ES2167571T3 (cg-RX-API-DMAC7.html)
IL (1) IL122242A (cg-RX-API-DMAC7.html)
NO (1) NO318184B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ310730A (cg-RX-API-DMAC7.html)
PL (1) PL185150B1 (cg-RX-API-DMAC7.html)
PT (1) PT831910E (cg-RX-API-DMAC7.html)
RO (1) RO118046B1 (cg-RX-API-DMAC7.html)
RU (1) RU2166330C2 (cg-RX-API-DMAC7.html)
WO (1) WO1996040257A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2336876C2 (ru) * 2002-05-29 2008-10-27 Новартис Аг Комбинация ингибитора дипептидилпептидазы iv (dpp iv) и сердечно-сосудистого вещества

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277018C (en) * 1997-01-10 2006-10-03 Merck & Co., Inc. Use of angiotensin ii antagonists to treat symptomatic heart failure
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
HK1042252B (en) * 1999-03-05 2004-04-23 G.D. Searle Llc Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
JP2004501099A (ja) * 2000-05-11 2004-01-15 フアルマシア　コーポレイション アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
DE60127410T2 (de) * 2000-07-27 2007-12-13 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
ES2269442T3 (es) * 2000-07-27 2007-04-01 Pharmacia Corporation Terapia de combinacion de antagonista de aldosterona e inhibidor de ciclooxigenasa-2 para prevenir o tratar trastornos cardiovasculares relacionados con la inflamacion.
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003233946A1 (en) * 2002-03-15 2003-09-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20070123498A1 (en) * 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
US20080032960A1 (en) 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2010007418A (es) * 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
TWI468410B (zh) 2009-01-30 2015-01-11 Takeda Pharmaceutical 稠環化合物及其用途
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
MX375194B (es) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
KR102538999B1 (ko) 2016-06-29 2023-05-31 유니버시떼 드 몬트리얼 비아릴메틸 헤테로사이클
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
RS65963B1 (sr) 2018-10-29 2024-10-31 Myokardia Inc Tetrahidropiran (thp)-supstituisana biciklična jedinjenja pirimidindiona
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12044455B2 (en) 2021-08-20 2024-07-23 Pioneer Family Brands, Inc. Ice shaver with thermally isolated shave deck
US11971205B2 (en) 2021-08-20 2024-04-30 Pioneer Family Brands, Inc. Ice shaver with splash guard
US11982483B2 (en) 2021-08-20 2024-05-14 Pioneer Family Brands, Inc. Ice shaver with multi-link control arm

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
EP0481448A1 (en) * 1990-10-16 1992-04-22 E.R. SQUIBB & SONS, INC. Dihydropyrimidine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
EP0586513A1 (en) * 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
WO1994009778A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481448A1 (en) * 1990-10-16 1992-04-22 E.R. SQUIBB & SONS, INC. Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2336876C2 (ru) * 2002-05-29 2008-10-27 Новартис Аг Комбинация ингибитора дипептидилпептидазы iv (dpp iv) и сердечно-сосудистого вещества

Also Published As

Publication number Publication date
CA2224079A1 (en) 1996-12-19
ATE209047T1 (de) 2001-12-15
CN1522701A (zh) 2004-08-25
RO118046B1 (ro) 2003-01-30
PL185150B1 (pl) 2003-03-31
DK0831910T3 (da) 2002-05-21
PT831910E (pt) 2002-05-31
NO975741L (no) 1998-01-29
US6653306B1 (en) 2003-11-25
KR100618466B1 (ko) 2006-12-13
JPH11507627A (ja) 1999-07-06
BR9609066A (pt) 1999-01-26
WO1996040257A1 (en) 1996-12-19
IL122242A (en) 2001-07-24
IL122242A0 (en) 1998-04-05
KR19990022548A (ko) 1999-03-25
PL324001A1 (en) 1998-04-27
EP0831910A1 (en) 1998-04-01
NO318184B1 (no) 2005-02-14
AU725689B2 (en) 2000-10-19
CN1192697A (zh) 1998-09-09
DE69617235D1 (de) 2002-01-03
CZ297975B6 (cs) 2007-05-09
EP0831910B1 (en) 2001-11-21
CN1142793C (zh) 2004-03-24
AU6157796A (en) 1996-12-30
NZ310730A (en) 2001-01-26
DE69617235T2 (de) 2002-07-25
CZ385097A3 (cs) 1998-06-17
NO975741D0 (no) 1997-12-05
ES2167571T3 (es) 2002-05-16

Similar Documents

Publication Publication Date Title
RU2166330C2 (ru) Комбинация, содержащая антагонист рецептора ангиотензина ii и эпоксистероидный антагонист рецептора альдостерона
EP0831911B1 (en) Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
US20040053903A1 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist
US20040067915A1 (en) Method to treat cardiofibrosis with a combination of an angiotensin II antagonist and spironolactone
US20110229571A1 (en) Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker
RU2384346C2 (ru) Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
AU2003202486B2 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
AU4264200A (en) Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure
WO2007053406A1 (en) Combinations of antihypertensive and cholesterol lowering agents
EP1469862A2 (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
HK1096293B (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090606